Several classes of orally administered HDAC inhibitors have been found to attenuate the progression of certain cancers and neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease (Chuang et al., 2009). This evidence concerns the gene HDAC9 and juvenile Huntington disease.